For decades, the little blue inhaler was a lifeline for millions of people with asthma. But doctors now know it can make the condition worse - and a quiet revolution in treatment is already ...

Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma TA1149 30 April 2026 30 April 2026 Vorasidenib for treating astrocytoma ...

Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula HTG777 15 April 2026 15 April 2026 ...

This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...

A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

Fezolinetant (also called Veoza and made by Astellas Pharma) is recommended to treat moderate to severe symptoms in final draft NICE guidance. Hot flushes and night sweats can hugely affect daily life ...

Holding our meetings in public supports our commitment to having processes in place that are rigorous, open, and transparent.

Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based ...

Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more ...

Suggested remit: To appraise the clinical and cost effectiveness of givinostat within its marketing authorisation for treating Duchenne muscular dystrophy in people 6 years and over. Anticipate the ...

This guidance has been updated and replaced by NICE guideline CG172 ...

We have moved Medical technologies guidance 71 to become HealthTech guidance 638. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...